InfuSystem (INFU) CEO Carrie Lachance Receives Awards

What Happened Carrie Lachance, President, CEO and Director of InfuSystem Holdings, Inc., received two equity awards reported on Form 4 for a 2026-05-12 grant date: an option covering 62,117 shares (reported at $0) and 29,816 restricted stock units (RSUs) (reported at $0). These were reported as awards/derivative acquisitions (code A) — not open-market buys or sales — so there was no cash outlay reported with the filing.

Key Details

• Transaction date: May 12, 2026; Form 4 filed May 14, 2026 (filed within the normal 2-business-day window).
• Grants: 62,117-share option (reported price $0); 29,816 RSUs (reported price $0).
• Total shares subject to awards: 91,933.
• Vesting and conversion (from filing footnotes):
  • Option vests in four equal annual installments beginning May 12, 2027. (F1)
  • RSUs convert to common stock one-for-one. (F2)
  • RSUs vest in three equal annual installments beginning May 12, 2027. (F3)
• Shares owned after the transaction: not specified in the information provided here.

Context These are compensation/award grants (derivative instruments) rather than purchases or sales. The option gives the right to acquire shares subject to vesting; RSUs convert to common stock as they vest. Reported grant price of $0 reflects the filing’s reported acquisition price but does not state the economic value or potential intrinsic value, which depends on future market price and the specified exercise terms.